GleamWall
中文EN

PTHS Pelthos Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1919246 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin83.2%
Operating margin-101.6%
Net margin-152.2%
FCF margin-63.5%
EBITDA margin-98.9%

Returns

ROE-299.8%
ROA-61.2%
ROIC (approx.)-408.1%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio1.78x
Interest coverage-6.26x

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-35.9%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$15.39M$15.60M$10.91M$9.39M$7.41M$0$0—
Cost of revenue$1.66M$3.61M$1.67M$1.67M$2.32M$0$0—
Gross profit$13.73M$11.99M$9.23M$7.72M$5.09M$0$0—
R&D expense$1.02M$600,000$186,000$374,000$145,000$515,000$194,000$285,000
SG&A expense$18.84M$27.67M$21.10M$18.47M$18.38M$2.72M$1.64M$1.54M
Operating income-$9.69M-$17.32M-$13.09M-$12.00M-$15.36M-$3.23M-$1.83M-$1.82M
Interest expense$2.27M$2.39M$2.35M$1.31M$1.35M$218,000$134,000$108,000
Pretax income-$7.89M-$23.42M-$25.07M-$28.59M-$16.70M-$3.45M-$1.97M-$1.93M
Income tax$0$0$0-$6.92M-$465,000$0$0—
Net income-$7.89M-$23.42M-$25.07M-$21.66M-$16.24M-$3.45M-$1.97M-$1.93M
EBITDA-$9.41M-$17.05M-$12.62M-$11.66M-$14.97M-$3.23M-$1.83M—
EPS (basic)-2.04-6.62-7.57—-5.30-5.29-3.21—
EPS (diluted)-2.04-6.62-7.57—-5.30-5.29-3.21—
Weighted avg. shares (diluted)3.86M3.54M3.31M—3.06M651,921612,889—
Balance sheet
Cash & equivalents$17.69M$24.19M$31.98M$17.97M$14.20M$59,000$131,000$513,000
Receivables$13.41M$14.48M$11.70M$8.86M———$0
Inventory$21.47M$21.47M$23.42M$23.57M$24.10M——$0
Current assets$56.07M$63.36M$69.80M$53.41M$49.76M$822,850$911,179$1.37M
PP&E, net$8.51M$8.88M$9.31M$9.59M$10.17M——$0
Goodwill$24.68M$24.68M$24.68M$24.68M$30.62M——$0
Intangibles$36.34M$37.40M$38.44M$39.47M$32.52M——$0
Total assets$128.82M$137.36M$145.38M$130.40M$126.43M$822,850$911,179$1.37M
Current liabilities$31.43M$31.96M$25.00M$25.99M$24.77M$7.32M$5.11M$4.08M
Total liabilities$135.00M$138.86M$126.11M$91.52M$68.18M$7.32M$5.11M$4.08M
Shareholders' equity-$6.19M-$1.50M$19.27M$38.88M$58.25M-$6.50M-$4.20M-$2.71M
Shares outstanding3.90M3.72M3.37M3.23M3.09M673,3206.18M610,389
Cash flow statement
Operating cash flow-$5.16M-$7.66M-$13.13M-$6.25M-$15.26M-$447,000-$632,000-$670,000
Capital expenditure$60,000$2,000$194,000$99,000$0$0$0—
Free cash flow-$5.22M-$7.67M-$13.32M-$6.35M-$15.26M-$447,000-$632,000—
Investing cash flow-$60,000-$2,000-$194,000-$8.00M$2.76M$0$0—
Financing cash flow-$1.17M$0$27.52M$18.02M$26.69M$375,000$250,000-$72,000
Depreciation & amortization$283,000$278,000$469,000$340,000$389,000$0$0—
Stock-based compensation$1.94M$2.76M$1.91M$1.80M$2.81M$394,000$486,000$530,000

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.